SHR-A1811 + SHR-1316 + 5-fluorouracil

A combination therapy consisting of SHR-A1811, SHR-1316, and 5-fluorouracil is under investigation primarily for oncology indications in solid tumors, particularly HER2-expressing or mutated cancers.\n- **SHR-A1811** is a third-generation antibody-drug conjugate (ADC) composed of a monoclonal antibody (anti-HER2, like trastuzumab), a cleavable linker, and a topoisomerase I inhibitor payload. It exerts its antitumor effect by targeting HER2 (ErbB-2), internalizing into cancer cells, and releasing the cytotoxic agent to induce DNA damage and cell death[1][3][5].\n- **SHR-1316** is a PD-L1 (programmed death-ligand 1) monoclonal antibody (checkpoint inhibitor), designed to block the PD-1/PD-L1 pathway, thereby promoting T-cell mediated immune responses against tumor cells.\n- **5-fluorouracil (5-FU)** is a widely used antimetabolite chemotherapy agent that inhibits thymidylate synthase, disrupting DNA synthesis and repair in rapidly dividing cancer cells[2][4][6].\nThis combination leverages both targeted cytotoxicity (SHR-A1811), immune checkpoint inhibition (SHR-1316), and direct cytotoxic chemotherapy (5-fluorouracil)[1][2][5].

Other names

5-FU